CG Oncology, Inc. Common stock (CGON)

CG Oncology, Inc. Common stock (CGON) — VMCI valuation read

The headline on CG Oncology, Inc. Common stock (CGON) is a 33/100 VMCI score, set against a Healthcare sector median of 50. That 17-point below-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value drag is in the data.

CGON insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** CGON trades at 23.0x earnings, 28% above the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 1.9x is the rate-sensitivity line to watch sets the risk side, the three lines a value buyer reads first on CGON.

CGON rose 2.2% over the trailing 7 days, with a -17.6% read on a 30-day basis.